19992-95-1 Usage
Chemical structure
A guanidine compound with a 4-chlorophenyl)-phenyl-methylidene group attached to the amino group
Classification
Adenosine A2A receptor agonist
Potency
Potent and selective
Use
Commonly used in scientific research to study the role of adenosine receptors in physiological processes
Effects
Significant effects on the cardiovascular system, neurotransmission, and inflammation
Therapeutic potential
Being investigated for potential applications in conditions such as Parkinson's disease, inflammation, and cardiovascular disorders
Medication development
Offers potential for the development of new medications targeting adenosine receptors for the treatment of various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 19992-95-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,9,9 and 2 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 19992-95:
(7*1)+(6*9)+(5*9)+(4*9)+(3*2)+(2*9)+(1*5)=171
171 % 10 = 1
So 19992-95-1 is a valid CAS Registry Number.
19992-95-1Relevant academic research and scientific papers
Novel molecular hybrids of cinnamic acids and guanylhydrazones as potential antitubercular agents
Bairwa, Ranjeet,Kakwani, Manoj,Tawari, Nilesh R.,Lalchandani, Jaya,Ray,Rajan,Degani, Mariam S.
supporting information; experimental part, p. 1623 - 1625 (2010/06/16)
In an attempt to identify potential new agents active against tuberculosis, 20 novel phenylacrylamide derivatives incorporating cinnamic acids and guanylhydrazones were synthesized using microwave assisted synthesis. Activity of the synthesized compounds was evaluated using resazurin microtitre plate assay (REMA) against Mycobacterium tuberculosis H37Rv. Based on empirical structure-activity relationship data it was observed that both steric and electronic parameters play major role in the activity of this series of compounds. Compound 7s (2E)-N-((-2-(3,4-dimethoxybenzylidene) hydrazinyl) (imino) methyl)-3-(4-methoxyphenyl) acrylamide showed MIC of 6.49 μM along with good safety profile of >50-fold in VERO cell line. Thus, this compound could act as a potential lead for further antitubercular studies.
